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Abstract
Renal cell carcinoma (RCC) occurs in sporadic and heritable forms. Genetic mutations have been identified as risk factors in 
1–2% of RCC. The aim of this study was to evaluate I157T and CHEK2*1100delC mutations of checkpoint kinase 2 (CHEK2) 
gene in RCC. Medical records of 40 clear cell RCC patients who had genetic tests and consultation at the Genetic Outpatient 
Clinic, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, were reviewed 
retrospectively. Mutation profile was assessed by ASA-PCR and RFLP-PCR techniques. Only three female patients had CHEK2 
mutation (I157T). No CHEK2*1100delC was observed in any of the patients. These tumors were N0, and two were Grade 3. 
One showed capsular infiltration. No blood vessel infiltration or metastases was observed. Overall, RCC from patients with 
CHEK2 mutation did not display any special characteristics when compared with those without the mutation. While no associ-
ation  between CHEK2 mutation and RCC could be established, all three patients with CHEK2 mutation developed second neo-
plasms many years after first diagnosis. Further studies, especially regarding CHEK2 mutation as a predictive factor for second 
 neoplasm in RCC patients, are warranted.
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Introduction
Renal cell carcinoma (RCC) accounts for about 4% of  all 
adult malignancies. RCC occurs in both sporadic and her-
itable forms (1). Genetic mutations have been identified as 
the cause of  inherited cancer in 1–2% of  RCC. Epidemio-
logic data suggest that a family history of  RCC is a risk fac-
tor for the disease (2). The best-known hereditary cancer 
predisposition syndrome that leads to clear cell RCC is 
von Hippel–Lindau (VHL) disease (3, 4). Familial clear 
cell RCC is the most frequently diagnosed condition as a 
consequence of  aberrations in VHL gene (2). Apart from 
VHL, mutations of  MET, FLCN, TSC1, TSC2, FH, and 
SDH genes also are risk factors for the development of 
RCC (5, 6).
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The human tumor suppressor gene checkpoint kinase 2 
(CHEK2), located on chromosome 22q12.1, contains 14 
exons (7). The gene encodes protein kinase Chk2 (cell-cy-
cle-checkpoint of  proteins kinase 2), which is crucial for 
the maintenance of  genome integrity and the regulation of 
G2/M cell-cycle-checkpoint (8). The Chk2 enzyme plays a 
crucial role in ensuring accurate DNA repair in response 
to. CHEK2 also acts as a tumor suppressor by promoting 
 genomic stability, enabling DNA repair, and inducing apop-
tosis (7). In response to DNA damage, CHEK2 is activated 
via ATM-dependent pathway and phosphorylates several 
substrates such as p53, BRCA1, CDC25A, and CDC25C. 
CHEK2 mutation has been reported in breast cancer (8–15), 
colorectal cancer (16, 17), malignant melanoma (18), and 
bladder cancer (17, 19). Especially, the polymorphic vari-
ant of  CHEK2 gene (1100delC) is associated with increased 
risk of  breast, prostate, colorectal, and thyroid cancers (9, 
10, 20), whereas the missense variant I157T, in addition to 
the above cancers, is known to increase the risk of  kidney 
cancer, ovarian adenocarcinoma, and borderline ovarian 
cancers (16, 21).
Although sparse, the available data suggest a role for 
CHEK2 in RCC. Trubicka et al. showed that the consti-
tutive mutation I157T in CHEK2 gene is responsible for 
the development of  ccRCC (22). Ge et al. reported that a 
rare variant of  CHEK2, rs17879961, was associated with 
decreased risk of  renal cell cancer (23). A study by Ghata-
lia et al. (24), which compared intra-patient kinase gene 
 expression between RCC and matched normal kidney 
samples, identified CHEK2 as one of  the top 10 overex-
pressed kinases in metastatic RCC, suggesting a patholog-
ical role of  activated CHEK2 in RCC. The aim of  this 
retrospective study was to further evaluate the role of 
I157T and CHEK2*1100delC mutations of  CHEK2 gene 
in ccRCC.
Material and Methods
Medical records of  40 ccRCC patients who were diagnosed 
and/or treated at the Outpatient Clinic, Maria Skłodows-
ka-Curie Memorial Cancer Center and Institute of  Oncol-
ogy, Gliwice Branch, Poland, were reviewed. This was done 
according to the national guidelines. All patients signed 
written informed consent allowing the use of  their biolog-
ical material for clinical research. The patients had genetic 
tests and consultation at the clinic. The primary reason for 
these patients seeking genetic counseling was a history of 
cancer in the family. Mutation profile was performed as 
per the standardized procedure of  the clinic. In brief, DNA 
was isolated from 10 mL peripheral blood sample. Status 
of  CHEK2*1100delC and I157T mutations was assessed 
by ASA-PCR and RFLP-PCR techniques, respectively. In 
each amplification, both positive and negative controls were 
used. The 1100delC is a rare variant that leads to premature 
protein truncation. The relatively common missense variant 
I157T is the result of  the substitution of  isoleucine 157 by 
threonine.
The following inclusion criteria were applied: 
 microscopic confirmation of  ccRCC; performance status 
ZUBROD 0–1; age above 18; and renal (creatinine, urea, 
GFR), liver (transaminase and bilirubin levels), and bone 
marrow  (hemoglobin concentration, white blood cell 
count, platelet count) functions within the normal range. 
Data on age at onset, co-morbid conditions, cigarette 
smoking, surgical procedure, TNM classification, his-
tology, Fuhrman grade, history of  cancer in family, and 
second neoplasm were gathered from hospital records and 
pathology reports.
Statistical analyses were carried out using STATISTICA 
7 software. The qualitative features are presented as the per-
centage of occurrence and evaluated with Fisher test and Chi 
squared test with Yates correction. Differences were consid-
ered significant if  the P-value was ≤ 0.05.
Results
Patient characteristics
The patient characteristics are shown in Table 1. All 
 patients had nephrectomy due to kidney cancer, and all 
were confirmed to have ccRCC upon histopathologic ex-
amination. The median age of  patients at diagnosis was 
52.5 years (range from 25 to 78), and 60% of  patients were 
≥50 years old. The majority of  the patients were women 
(75% women vs. 25% men, P = 0.159; Table 1). Co-morbid 
conditions were observed in 55% of  patients. The predom-
inant co-morbidities were cardiovascular diseases (35%) 
and diabetes (13%). None of  the patients had a history of 
viral diseases. Cigarette smoking was reported in 32.5% of 
patients.
Table 1. Clinical characteristics of the kidney cancer patients.
Factors n %
Gender Women
Men
30
10
75
25
Age ≥50
<50
24
16
60
40
Co-morbid 
condition
Yes
No
22
18
55
45
Diabetes No
Yes
35
5
87.5
12.5
Cardiovascular 
diseases
No
Yes
26
14
65
35
Viral diseases No
Yes
40
0
100
0
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Mutation and tumor characteristics
The mutation status and tumor characteristics are summa-
rized in Table 2. Only three patients had CHEK2 mutation 
(I157T), and all were females. CHEK2*1100delC was not 
observed in any of the patients. These tumors were N0 and 
less than 10 cm in size. Two were Grade 3, and one showed 
capsular infiltration. No blood vessel infiltration or metasta-
ses was observed. Overall, RCC from patients with CHEK2 
mutation showed no special characteristics when compared 
with RCC from patients without CHEK2 mutation.
Family history and secondary neoplasms
Cancer in family history was reported in 70% of patients 
(Table 3). The predominant was colorectal cancers (35%), fol-
lowed by breast cancer (25%), gynecological cancers (15%), 
and renal cell cancer (12.5%). Our results showed no asso-
ciation between CHEK2 mutation and cancer in the family. 
In all patients with CHEK2 mutation, second neoplasms de-
veloped many years after the first diagnosis: breast cancer 15 
years post-nephrectomy; renal cancer 2 years post-nephrec-
tomy; and meningioma 9 years post-nephrectomy.
Discussion
In this retrospective study, we analyzed the presence of 
CHEK2 mutation and its relationship with cancers in fam-
ily history of patients with ccRCC. Interestingly, there were 
more women than men in the study group, a factor that is 
contradictory to the established norm that RCC is more 
prevalent in men than in women. The reason for this discrep-
ancy is not clear. However, given that the study population 
is patients seeking genetic counseling because of a history 
of cancer in the family, it appears to confirm the notion 
that men are less willing than women to participate in reg-
ular screening processes. Overall, CHEK2 mutation (variant 
I157T) was detected in only three patients. CHEK2 mutation 
neither appeared to have conformed any special characteris-
tics to these tumors nor had a role in family history.
The putative role of CHEK2 mutation has been reported 
in other cancers. For example, Cybulski et al. reported that 
while the I157T CHEK2 mutation increases the risk of col-
orectal cancer in Polish population, truncating mutations 
may be associated with a low or no risk (16). Similar results 
(an increased risk of sporadic and familiar colorectal cancer 
in patients with CHEK2 I157T mutation) were reported by 
Kilpivaara et al. (17). The increased risk of breast cancer in 
patients with CHEK2 mutation is supported by many stud-
ies (9, 11, 12). CHEK2 missense variant I157T is found to 
be associated with a 1.5-fold risk of breast cancer (13), and 
CHEK2*1100delC heterozygosity is associated with a three-
fold risk of breast cancer in women in the general popula-
tion (14). A meta-analysis conducted in 26,000 patients and 
27,000 controls showed that CHEK2*1100delC increases the 
risk of breast cancer three-to five-fold. The risk of breast 
cancer at age 70 years in CHEK2*1100delC heterozygotes is 
almost as high as that for BRCA1 and BRCA2 mutation het-
erozygotes (15). In some meta-analyses, CHEK2*1100delC 
heterozygotes have a two-fold risk of malignant melanoma 
(18).In addition, Złowocka et al. have found that CHEK2 
mutations increase the risk of bladder cancer (19). In our 
previous study, breast cancer patients with CHEK2 mutation 
were characterized by older age, history of gastric cancer in 
family, and lower stage of disease (10). Pertinent to RCC, a 
Table 2. Mutation and histological characteristics of the kidney cancer patients.
Factors n % CHEK2 I157T (%)
Clinical staging nodes N0
N1-N3
39
1
97.5
2.5
3 (100)
0
Tumor size T<10 cm
T>10 cm
39
1
97.5
2.5
3 (100)
0
Grade G G1+2
G3
34
6
85
15
1 (33.3)
2 (66.7)
Blood vessels infiltration No
Yes
Missing
36
3
1
90
7.5
2.5
3 (100)
0
0
Adrenal gland metastases No
Yes
Missing
37
2
1
92.5
5
2.5
3 (100)
0
0
Capsule infiltration No
Yes
Missing
33
6
1
82.5
15
2.5
2 (66.7)
1 (33.3)
0
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relationship with CHEK2 mutations has been reported pre-
viously (9, 25). Specifically, the missense variant I157T was 
associated with an increased risk of kidney cancer (9). In the 
current study, no such relationship could be established.
The caveat of this study is that this is a single-center ret-
rospective study with only 40 patients. However, the most 
important finding is that all three patients with CHEK2 mu-
tation developed second neoplasms. Thus, the study provides 
a rationale for further exploration of the role of CHEK2 mu-
tation in RCC, especially its utility as a predictive factor for 
secondary neoplasms.
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